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ILLUSTRATIVE CASE
Two weeks ago, you informed your 
patient—a 53-year-old man with a body 
mass index of 28.4—that he has type 2
diabetes. Since then, he has seen a 
nutritionist and begun exercising regularly. 
His hemoglobin A1c (HbA1c) is 7.7%. 
You recommend that he begin taking 
metformin. The patient is worried about 
the potential for oral antidiabetic agents to 
cause hypoglycemia. He’s aware that many 
patients with diabetes monitor their blood 
sugar levels at home and wants to know 
if he should, too. You wonder whether it’s 
necessary, or even advisable, to initiate 
self-monitoring at this time. 
For patients with type 2 diabetes, self-monitoring of blood glucose makes intuitive sense. Theoreti-
cally, it reinforces self-management 
behaviors, promotes adherence to the 
prescribed medication regimen, and 
leads to better glucose control. It seems 
obvious, too, that patients taking medi-
cations intended to lower blood sugar 
need to be aware of their glucose levels 
so they can take action to reduce the 
risk of complications.
But things that make sense intuitively 
do not always stand up to scrutiny. New 
high-quality evidence suggests that for 
those with newly diagnosed diabetes, 
self-monitoring of blood glucose may do 
more harm than good. 
❚  More questions 
than answers 
While it is generally accepted that glucose 
self-monitoring is useful for those with 
insulin-treated type 2 diabetes,2-4 evi-
dence supporting the practice for patients 
with diabetes who do not require insu-
lin is limited. Two recent meta-analyses 
of RCTs5,6 found that self-monitoring 
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of blood glucose achieves a statistically 
signifi cant reduction of 0.4% in HbA1c; 
the quality of the studies, however, 
was limited. A well-designed RCT was 
needed, the researchers concluded, to 
settle questions about the value of self-
monitoring.
The most recent Cochrane review7 
of self-monitoring reached a similar 
conclusion: The reviewers called for 
additional research into the benefi ts 
of self-monitoring for patients with 
diabetes who do not need insulin. The 
reviewers also emphasized the need 
for information on patient-related 
outcomes such as quality of life, well-
being, and satisfaction.
Are recommendations out of step?
Despite the lack of defi nitive evidence, 
the Department of Health and Human 
Services calls on us to increase the pro-
portion of patients with diabetes who 
monitor their blood sugar at least once 
daily to 60% as part of its Healthy 
People 2010 initiative.8 The American 
Diabetes Association states that self-
monitoring of blood glucose may help 
patients taking oral antidiabetic agents 
achieve glycemic goals.9 And the Inter-
national Diabetes Federation recom-
mends that self-monitoring of blood 
glucose be offered to all people with 
type 2 diabetes taking insulin or oral 
agents—and be part of the patient edu-
cation that is given to all those who are 
newly diagnosed.10
But all of these groups may need to 
rethink their recommendations in light 
of the latest fi ndings from the O’Kane 
RCT. 
 
STUDY SUMMARY
❚  Self-monitoring has little 
effect on glycemic control
O’Kane and colleagues conducted a pro-
spective RCT comparing self-monitoring 
versus no monitoring among 184 people 
with newly diagnosed type 2 diabetes.1 
Patients were randomized to the self-
monitoring or control group for 1 year, 
with clinic visits at 3-month intervals. 
Those who were already taking insulin 
or had engaged in self-monitoring of 
blood glucose were excluded. 
At baseline, there was no signifi cant 
difference in HbA1c, age, or sex be-
tween the 2 groups. Participants in both 
groups underwent identical diabetes ed-
ucation programs throughout the study 
period and received dietary and medical 
management based on the same treat-
ment algorithm. Patients whose baseline 
HbA1c was >7.5% received metformin, 
followed by the sulfonylurea gliclazide 
if they did not reach target at the maxi-
mum dose of metformin. There was no 
signifi cant difference in medication use 
at baseline or at 12 months. 
Patients in the self-monitoring group 
were given glucose monitors and asked 
to record 4 fasting and 4 postprandial 
capillary blood glucose measurements 
per week. They were also taught to 
monitor and interpret blood glucose 
readings, and to respond appropriately 
to high or low readings. 
At each follow-up visit, patients 
underwent blood tests for HbA1c, 
lipids, and electrolyte levels and com-
pleted questionnaires about treatment 
satisfaction, attitudes about diabetes, 
and levels of depression, anxiety, and 
well-being. Adherence to self-moni-
toring was verifi ed by downloading 
meter readings. The dropout rate was 
low (2.2%), and adherence in the self-
monitoring group was high. Study re-
sults were assessed using intent-to-treat 
analysis.
HbA1c fell in both the self-monitor-
ing and control groups, with no signifi -
cant differences at any point. The mean 
(standard deviation) value at 12 months 
was 6.9% (0.8%) in the self-monitor-
ing group, compared to 6.9% (1.2%) 
in the control group, with a 95% confi -
dence interval for the change in HbA1c 
of –0.25% to 0.38%. Throughout the 
study period, there was no difference in 
use of oral hypoglycemic medications or 
reported hypoglycemia.
PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
At the end of 
12 months, the 
mean HbA1c was 
6.9% for both the 
self-monitoring 
and control groups
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Glucose self-monitoring
Self-monitoring linked 
to depression
Measures of depression and anxiety 
were scored on a 100-point scale and 
compared to baseline measurements. 
At 12 months, participants in the self-
monitoring group were more depressed, 
scoring 6% higher, on average, on the 
depression subscale of the well-being 
questionnaire (P=.01) than those in the 
control group. There was a trend toward 
increased anxiety in the self-monitoring 
group, but no signifi cant differences in 
well-being, energy, or any of the other 
diabetes attitude subscales. 
WHAT’S NEW
❚  Less may be better
Because we emphasize self-management 
skills when we counsel patients about 
diabetes, it is surprising to learn that 
knowledge about glycemic control and 
blood sugar levels does not lead to bet-
ter glycemic control. This RCT provides 
strong evidence that more information is 
not necessarily desirable, at least for pa-
tients with newly diagnosed type 2 diabe-
tes who do not need insulin. 
Depression is a known complication 
of diabetes. It affects an estimated 10% 
to 30% of patients with diabetes, who 
have double the odds of depression com-
pared to people without diabetes.11,12 Pa-
tients with depression and diabetes have 
poorer glycemic control,13,14 an increased 
risk of complications,15-17 a decreased 
quality of life,18 an increased disability 
burden,19,20 and increased health care use 
and costs.18,21,22 In addition, they face a 
signifi cantly higher risk of death from all 
causes, beyond the risks associated with 
depression or diabetes alone.23
CAVEATS
❚  Patients on sulfonylureas 
may be an exception
This study used metformin as the initial 
oral medication, with sulfonylureas re-
served for those who did not reach target 
glycemic control with maximum metfor-
min therapy. The number of patients tak-
ing sulfonylureas was 11 in the self-mon-
itoring group and 6 in the control group. 
Because hypoglycemia is a concern in 
patients taking sulfonylureas, there may 
be a role for self-monitoring of blood 
glucose in these patients.
Also of note: This study does not 
provide defi nitive evidence that self-mon-
itoring of blood glucose causes harm. 
Although self-monitoring was associated 
with a 6% higher score on a depression 
subscale and a trend toward increased 
anxiety, overall satisfaction with treat-
ment was similar in both groups. Ad-
ditional studies are needed to better 
understand the relationship between self-
monitoring and depression.
Self-monitoring may still be a good 
idea for certain patients, regardless of 
their diabetic medication regimen. When 
evaluating the potential benefi ts of self-
monitoring of blood glucose, physicians 
should consider the individual’s predis-
position to depression, among other 
concerns. 
CHALLENGES TO IMPLEMENTATION
❚  Hard to forego a practice 
that everyone expects 
Self-monitoring serves different purposes 
for different populations. Blood glucose 
levels, along with HbA1c, can guide cli-
nicians in making treatment decisions. 
Knowing blood sugar levels may be edu-
cational or empowering to patients, and 
provides critical information if hypogly-
cemia is a concern. These considerations 
lead us to conclude that while self-moni-
toring is not indicated for all newly diag-
nosed diabetic patients, it should be con-
sidered in selected circumstances. 
Because of the prevalence of self-mon-
itoring of blood glucose, patients may see 
it as a key component of an optimal self-
management regimen. It may be hard to 
convince patients with newly diagnosed 
diabetes otherwise—and to convince 
some clinicians that there is little benefi t 
in recommending it. Again, clinical judg-
ment is required. We suspect, however, 
that with the proper explanation, many 
Those in the self-
monitoring group 
were more 
depressed, scoring 
6% higher, on 
average, on the 
depression 
subscale than 
the controls
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patients will be relieved to learn that they 
will not have to prick their fi ngers regu-
larly or record their blood glucose. ■
Acknowledgements
The PURLs Surveillance System is supported in part by 
Grant Number UL1RR024999 from the National Center 
for Research Resources, a Clinical Translational Sci-
ence Award to the University of Chicago. The content 
is solely the responsibility of the authors and does not 
necessarily represent the offi cial views of the National 
Center for Research Resources or the National Insti-
tutes of Health.
References
 1.   O’Kane MJ, Bunting B, Copeland M, Coates VE; 
ESMON study group. Effi cacy of self monitoring 
of blood glucose in patients with newly diagnosed 
type 2 diabetes (ESMON study): randomised con-
trolled trial. BMJ. 2008;336:1174-1177. 
 2.   McIntosh A, Hutchinson A, Home PD, et al. Clinical 
guidelines and evidence review for Type 2 diabe-
tes: management of blood glucose. 2002. Scharr, 
University of Sheffi eld. Available at: http://www.
nice.org.uk/pdf/NICE_full_blood_glucose.pdf. Ac-
cessed July 29, 2008.
 3.   Canadian Diabetes Association Clinical Practice 
Guidelines Expert Committee. Canadian Diabetes 
Association 2003 Clinical Practice Guidelines for 
the Prevention and Management of Diabetes in 
Canada. Can J Diabetes. 2003;27(suppl 2):S18-
S23. 
 4.   Karter AJ, Ackerson LM, Darbinian JA, et al. Self-
monitoring of blood glucose levels and glycemic 
control: the Northern California Kaiser Permanente 
Diabetes Registry. Am J Med. 2001;111:1-9.
 5.   Sarol JN Jr, Nicodemus NA Jr, Tan KM, Grava MB. 
Self-monitoring of blood glucose as part of a multi-
component therapy among non-insulin requiring 
type 2 diabetes patients: a meta-analysis (1966-
2004). Curr Med Res Opin. 2005;21:173-184.
 6.   Welschen LM, Bloemendal E, Nijpels G, et al. Self-
monitoring of blood glucose in patients with type 
2 diabetes who are not using insulin: a systematic 
review. Diabetes Care. 2005;28:1510-1517.
  7.   Welschen LM, Bloemendal E, Nijpels G, et al. Self-
monitoring of blood glucose in patients with type 
2 diabetes mellitus who are not using insulin. Co-
chrane Database Syst Rev. 2005;18(2):CD005060. 
 8.   US Department of Health and Human Services. 
Healthy People 2010. Increase the proportion of 
adults with diabetes who perform self-blood-glu-
cose-monitoring at least once daily. Available at: 
http://www.healthypeople.gov/document/html
/objectives/05-17.htm. Accessed July 29, 2008
 9.   American Diabetes Association. Executive summa-
ry: standards of medical care in diabetes—2008. 
Diabetes Care. 2008;31(suppl 1):S5-S11. Available 
at: http://care.diabetesjournals.org/cgi/content/full
/31/Supplement_1/S5. Accessed July 29, 2008. 
 10.   International Diabetes Federation Clinical Guide-
lines Taskforce. Global guidelines for type 2 diabe-
tes: recommendations for standard, comprehensive 
and minimal care. Diabetes Med. 2006;23:579-
593.
 11.   Anderson RJ, Freedland KE, Clouse RE, Lust-
man PJ. The prevalence of comorbid depression 
in adults with diabetes: a meta-analysis. Diabetes 
Care. 2001;24:1069-1078. 
 12.   Egede LE, Zheng D. Independent factors associ-
ated with major depressive disorder in a national 
sample of individuals with diabetes. Diabetes Care. 
2003;26:104-111. 
 13.   De Groot M, Jacobson AM, Samson JA, Welch G. 
Glycemic control and major depression in patients 
with type 1 and type 2 diabetes mellitus. J Psycho-
som Res. 1999;46:425-435.
 14.   Ciechanowski PS, Katon WJ, Russo JE, Hirsch IB. 
The relationship of depressive symptoms to symp-
tom reporting, self-care and glucose control in dia-
betes. Gen Hosp Psychiatry. 2003;25:246-252.
 15.   De Groot M, Anderson R, Freedland KE, Clouse 
RE, Lustman PJ. Association of depression and 
diabetes complications: a meta-analysis. Psycho-
som Med. 2001;63:619-630.
 16.   Black SA, Markides KS, Ray LA. Depression pre-
dicts increased incidence of adverse health out-
comes in older Mexican Americans with type 2 
diabetes. Diabetes Care. 2003;26:2822-2828. 
 17.   Kinder LS, Kamarck TW, Baum A, Orchard TJ. De-
pressive symptomatology and coronary heart dis-
ease in type I diabetes mellitus: a study of possible 
mechanisms. Health Psychol. 2002;21:542-552.
18.   Ciechanowski PS, Katon WJ, Russo JE. Depres-
sion and diabetes: impact of depressive symptoms 
on adherence, function, and costs. Arch Intern 
Med. 2000;160:3278-3285.
 19.   Egede LE. Diabetes, major depression, and func-
tional disability among U.S. adults. Diabetes Care. 
2004;27:421-428.
 20.   Egede LE. Effects of depression on work loss and 
disability bed days in individuals with diabetes. 
Diabetes Care. 2004;27:1751-1753.
 21.   Egede LE, Zheng D, Simpson K. Comorbid depres-
sion is associated with increased health care use 
and expenditures in individuals with diabetes. Dia-
betes Care. 2002;25:464-470.
 22.   Finkelstein EA, Bray JW, Chen H. Prevalence and 
costs of major depression among elderly claimants 
with diabetes. Diabetes Care. 2003;26:415-420.
 23.   Egede LE, Nietert PJ, Zheng D. Depression and all-
cause and coronary heart disease mortality among 
adults with and without diabetes. Diabetes Care. 
2005;28:1339-1345.
Having 
depression and 
diabetes 
signiﬁ cantly 
increases the risk 
of death from 
all causes 
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